MMWR

Morbidity and Mortality Weekly Report

World No Tobacco Day — May 31, 2010 (Box)

CDC
Division of News and Electronic Media
(404) 639-3286

No summary available

Tobacco Use and Awareness of Marketing Among Males and Females — Bangladesh, Thailand, and Uruguay, 2009

CDC
Division of News and Electronic Media
(404) 639-3286

Tobacco marketing plays a significant role in the initiation and maintenance of tobacco use. Although women account for only about 20 percent of the world′s 1.3 billion smokers, tobacco use among women is on the rise. Tobacco use reflects a complex interaction of personal, familial, cultural, and social factors, including exposure to tobacco industry marketing. Particularly troubling is new global data from Bangladesh, Thailand, and Uruguay, indicating greater exposure to cigarette marketing among young women (ages 15 to 24) than older women (over 24 years old). In addition, exposure to bidi (80.1 percent) and smokeless tobacco (69.9 percent) marketing was widespread among women in Bangladesh and did not vary by age. This report used data from the 2009 Global Adult Tobacco Survey to examine gender differences in tobacco use (smoked and smokeless) and awareness of tobacco marketing.

Attitudes Toward Mental Illness — United States, 2007

CDC
Division of News and Electronic Media
(404) 639-3286

This study across 37 states and territories found that in 2007, most adults (89 percent) agreed with the effectiveness of mental illness treatment, but fewer (57 percent) agreed about others being caring toward people with mental illness. Fewer adults with mental health symptoms believed that people are caring toward people with mental illness. Adults with mental health symptoms and negative attitudes might be less likely to reach out for support or seek needed care. Initiatives that can educate the public about how to support people with mental illness such as www.whatadifference.samhsa.gov, community stigma reduction initiatives and more media support for portrayals about mental illness recovery can reduce stigma for those seeking or receiving treatment for mental illness. People experiencing mental health difficulties are generally able to live a successful, full life, particularly if they receive treatment and support from friends, family members, and others to manage their illness.

FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP)

CDC
Division of News and Electronic Media
(404) 639-3286

On October 16, 2009, the Food and Drug Administration (FDA) licensed the bivalent human papillomavirus (HPV) vaccine (Cervarix®, produced by GlaxoSmithKline) for use in females aged 10 through 25 years. This is the second HPV vaccine licensed for use in females in the United States. The quadrivalent HPV vaccine (Gardasil®, produced by Merck and Co, Inc.) was licensed in 2006 for use in females aged 9 through 26 years. Both vaccines have high efficacy against vaccine type related cervical cancers. The bivalent HPV vaccine (Cervarix) is directed against two oncogenic types (HPV-16 and HPV-18) that cause about 70 percent of cervical cancers. The quadrivalent HPV vaccine (Gardasil) is directed against two oncogenic types (HPV-16 and HPV-18) that cause about 70 percent of cervical cancers and two non-oncogenic types (HPV-6 and HPV-11) that cause about 90 percent of genital warts. Both vaccines are given in a 3 dose series. On October 26, 2009 the Advisory Committee on Immunization Practices (ACIP) updated HPV vaccine recommendations. Vaccination is recommended with either HPV vaccine. ACIP recommends vaccination of girls at age 11 or 12 years. Vaccination is recommended for girls/women aged 13 through 26 years who have not been vaccinated previously or who have not completed the 3-dose series. ACIP recommends vaccination with bivalent or quadrivalent HPV vaccine for prevention of cervical cancers and precancers. ACIP recommends vaccination with quadrivalent HPV vaccine for prevention of cervical cancers and precancers and for prevention of genital warts.

FDA Licensure of a Quadrivalent Human Papillomavirus Vaccine (HPV4, Gardasil) for Use in Males and Guidance from the Advisory Committee on Immunization Practices (ACIP)

CDC
Division of News and Electronic Media
(404) 639-3286

On October 21, 2009, ACIP provided guidance that the quadrivalent HPV vaccine (Gardasil) may be given to males aged 9 through 26 years to reduce their likelihood of acquiring genital warts. ACIP does not recommend HPV4 for routine use among males. The vaccine is highly effective for prevention of genital warts, and is very safe. The vaccine would be most effective when given before exposure to HPV through sexual contact.

 

###

 

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES